Enterprise Value

1.612B

Cash

823.8M

Avg Qtr Burn

-29.84M

Short % of Float

10.63%

Insider Ownership

0.34%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Barzolvolimab (CDX-0159) (KIT receptor) Details
Prurigo nodularis, Skin disease/disorder

Phase 2

Data readout

Barzolvolimab (CDX-0159) Details
Eosinophilic Gastritis, Eosinophilic Esophagitis

Phase 2

Data readout

Phase 2

Data readout

Barzolvolimab (CDX-0159) (KIT receptor) Details
KIT/Mast cell diseases, Chronic spontaneous urticaria, Chronic urticaria

Phase 2

Data readout

CDX-585 Details
Solid tumor/s, Cancer

Phase 1

Data readout

CDX-1140 (CD40 agonist) Details
Solid tumor/s, Cancer, Diffuse large B cell lymphoma

Failed

Discontinued

Failed

Discontinued